- Home
- CALC
CALC
CalciMedica Inc.
as 06-05-2025 3:32pm EST
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | 26.7M | IPO Year: | N/A |
| Target Price: | $16.33 | AVG Volume (30 days): | 27.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.43 - $5.97 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of CalciMedica Inc. (CALC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bardin Stephen | CALC | Chief Financial Officer | May 30 '25 | Buy | $1.69 | 1,000 | $1,690.00 | 41,000 |
Latest CalciMedica Inc. News
CALC Breaking Stock News: Dive into CALC Ticker-Specific Updates for Smart Investing
PR Newswire
22 days ago
CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
PR Newswire
2 months ago
CalciMedica Announces Presentations at Upcoming Medical Meetings
PR Newswire
2 months ago
CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference
PR Newswire
2 months ago
CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates
PR Newswire
3 months ago
CalciMedica Secures Credit Facility for Up to $32.5 Million
PR Newswire
3 months ago
CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference
PR Newswire
4 months ago
CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference
PR Newswire
4 months ago
CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Compare CALC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CALC CalciMedica Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.